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Abstract
Background: Antihypertensive medications are widely prescribed by doctors and heavily promoted by
the pharmaceutical industry. Despite strong evidence of the effectiveness and cost-effectiveness of thiazide
diuretics, trends in both promotion and prescription of antihypertensive drugs favour newer, less cost-
effective agents. Observational evidence shows correlations between exposure to pharmaceutical
promotion and less ideal prescribing. Our study therefore aimed to determine whether print
advertisements for antihypertensive medications promote quality prescribing in hypertension.
Methods: We performed a cross-sectional study of 113 advertisements for antihypertensive drugs from
4 general practice-oriented Australian medical publications in 2004. Advertisements were evaluated using
a quality checklist based on a review of hypertension management guidelines. Main outcome measures
included: frequency with which antihypertensive classes were advertised, promotion of thiazide class drugs
as first line agents, use of statistical claims in advertisements, mention of harms and prices in the
advertisements, promotion of assessment and treatment of cardiovascular risk, promotion of lifestyle
modification, and targeting of particular patient subgroups.
Results: Thiazides were the most frequently advertised drug class (48.7% of advertisements), but were
largely promoted in combination preparations. The only thiazide advertised as a single agent was the most
expensive, indapamide. No advertisement specifically promoted any thiazide as a better first-line drug.
Statistics in the advertisements tended to be expressed in relative rather than absolute terms. Drug costs
were often reported, but without cost comparisons between drugs. Adverse effects were usually reported
but largely confined to the advertisements' small print. Other than mentioning drug interactions with
alcohol and salt, no advertisements promoted lifestyle modification. Few advertisements (2.7%) promoted
the assessment of cardiovascular risk.
Conclusion: Print advertisements for antihypertensive medications in Australia provide some, but not all,
of the key messages required for guideline-concordant care. These results have implications for the
regulation of drug advertising and the continuing education of doctors.
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Background
Hypertension is a major risk factor for cardiovascular dis-
ease [1] and the most common single problem managed
in Australian general practice. [2] For more than a decade
expensive new antihypertensive drugs have been pre-
scribed more frequently than the older and more cost
effective thiazide diuretics. [3-6] Newer antihypertensive
drugs are among the highest volume and cost items for the
Australian Pharmaceutical Benefits Scheme (PBS). [7] It is
estimated that adherence to guidelines favouring older,
less expensive agents in 1998 in Australia may have saved
$45 to $108 million. [3] These guidelines promote anti-
hypertensive drugs to augment lifestyle change, but not as
a substitute for such change. [1,8,9]
The content of print advertising for antihypertensive drugs
mirrors the trends away from cost-effective prescribing.
[10] There is observational evidence of associations
between doctors' prescribing and doctors' exposure to
advertisements. [11-16] Thus, heavy promotion may be at
least partly responsible for the more frequent prescribing
of newer drugs. Indeed, recognition that marketing influ-
ences prescribing has prompted government-funded
social marketing campaigns to encourage more cost-effec-
tive choices. [17] Doctors may not be aware of the degree
to which their prescribing is influenced by advertising.
[18]
The Medicines Australia Code of Conduct states that all
promotional information "must be current, accurate, bal-
anced and must not mislead either directly, by implica-
tion, or by omission". [19] The Australian National
Medicines Policy (NMP) states that each partner (includ-
ing the medicines industry) "accepts that all must be
engaged in a cooperative endeavour to bring about better
health outcomes for all Australians, focusing especially on
people's access to, and wise use of, medicines." The NMP
definition of "quality use of medicines" includes taking
into account "the potential risks and benefits of treat-
ment, dosage, length of treatment, and cost."[20] We
believe evidence-based guidelines are a useful standard
for evaluating how well advertisements support, rather
than lead away from, wise use of medicine. Thus, the aim
of our study was to determine whether print advertise-
ments for antihypertensive medications in Australia pro-
mote prescribing for hypertension that is concordant with
evidence-based guidelines. To answer this, we reviewed
evidence-based guidelines for important prescribing mes-
sages, and then looked for these messages in a sample of
advertisements from Australian medical publications.
At the time of performing our study, we were unaware of
any other similar studies regarding messages in advertise-
ments for antihypertensive medicines. Since then a study
of antihypertensive drug advertising in a Dutch journal
has been published. This study found 35% of the adver-
tisements contained claims unsupported by evidence.
[21] Our research builds on previous studies of advertise-
ments and promotional brochures which have found
overemphasis on relative statistical measures[22,23], and
claims lacking clarity, accuracy, balance and substantia-
tion. [22-25]
Methods
In the course of our literature review we identified several
major international hypertension guidelines from the
World Health Organisation, the US and Europe,[1,8,26]
as well as several Australian guidelines and prescribing
aids[9,27-29] and other recent publications. [30-34]
These were all current and relevant at the time we sampled
our advertisements. The guidelines agreed on several key
messages for the effective treatment of hypertension and
quality use of medicines (table 1). However they were not
entirely consistent on one important issue: the choice of
first- line drug. Although all guidelines endorsed thiazides
as a first-line drug class, some listed other classes as
equally first-line whilst some promoted thiazides specifi-
cally as the first-line class in the absence of compelling
indications for another class. This difference between
guidelines may arise from different interpretations of the
ALLHAT[31] and ANBP2 trials,[35] and from differing
emphasis on the importance of cost-effectiveness. Given
Table 1: Key messages in evidence-based hypertension management
• Modification of lifestyle. [1, 8, 9, 26-29, 32, 34]
• Assessment of overall cardiovascular risk. [1, 9, 26-29, 32, 34]
• Reduction of overall cardiovascular risk. [1, 8, 9, 26-29, 32, 34]
• Patients at low to medium risk may be given a longer trial of lifestyle changes before commencing pharmacotherapy. [9, 26-29, 32, 34]
• A range of drug treatments exists, including diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, 
and angiotensin receptor antagonists. [1, 8, 9, 26-29, 32, 34]
• The choice of antihypertensive drug may depend on characteristics of the patient, including other medical conditions or use of other medications. 
[1, 8, 9, 26-29, 32, 34]
• In the absence of compelling indications for a different agent, start drug treatment with a low-dose thiazide. [1, 8, 27-33]
• Thiazides are more cost-effective than newer agents in the management of hypertension. [1, 3, 30, 31]
• If a patient requires a combination of agents in the treatment of blood pressure, a low dose thiazide should usually form part of the combination. 
[1, 8, 29, 32]BMC Public Health 2008, 8:167 http://www.biomedcentral.com/1471-2458/8/167
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that the ALLHAT trial had in our opinion a stronger
design, and that the NMP definition of quality use of med-
icines includes consideration of costs, we regarded the rec-
ommendation of thiazides as the first-line class to be
correct.
Using these key messages from hypertension manage-
ment guidelines, we developed a quality checklist to
extract data from the advertisements (see additional file 1:
checklist.pdf). The checklist was used to measure promo-
tion of lifestyle modification, promotion of thiazides as
first line agents, promotion of cardiovascular risk assess-
ment, promotion of use of the drug for specific subgroups
of patients, and the mention of alternative antihyperten-
sive classes as treatment options (these issues are all
drawn from the quality prescribing messages in table 1).
We regarded advertisements as not fully promoting guide-
line-concordant care if they did not mention all of the
items on the check list. We also counted the frequency of
mention of drug harms and drug prices, because those fac-
tors are included in the NMP definition of quality use of
medicines. Finally, we assessed statistical claims, because
use of relative rather than absolute measures may have a
stronger influence on doctors' prescribing,[36,37] and
previous research has demonstrated a lack of reporting of
absolute measures in pharmaceutical advertisements and
brochures. [22,23]
We sampled advertisements for antihypertensive drugs
from four advertisement-rich, general practice-oriented
Australian medical publications. We drew these from
issues published between February and July of 2004,
inclusive. We examined every issue of the monthly publi-
cations (Australian Family Physician and Medicine Today)
and one randomly selected issue per month of each of the
weekly publications (Australian Doctor and  Medical
Observer). The random selection was based on randomly-
generated integers from a web-based random number
generator. [38] Our analysis included the largest advertise-
ment (by page area) for each antihypertensive drug in
each issue. Where two or more equally sized advertise-
ments for the same drug existed, both or all were
included. We excluded "short" advertisements (as defined
by the Medicines Australia Code of Conduct). [19]
We evaluated text and graphs in the advertisements, but
not imagery (thus, pictures of sports shoes, people swim-
ming, and so on were not counted as promotion of phys-
ical activity). We examined each entire advertisement
including contiguous "fine print", but we did not assess
further information on other pages of the journals. (Only
six advertisements in our sample of 113 referred readers to
such non-contiguous fine print.) For some items, we strat-
ified our findings according to whether information was
present in the "main body" of the advertisement; for these
purposes we excluded the "fine print" and "PBS Informa-
tion" sections of the advertisement (see additional file 1:
checklist.pdf).
Each advertisement was rated independently by two
authors, with disagreements resolved by consensus. By
designing a checklist which was largely "yes or no" in
available responses, we tried to minimise subjective inter-
pretative difficulties. Inter-rater reliability was not for-
mally calculated. The few inter-rater differences we found
were usually due to oversights, and consensus was easily
achieved. Descriptive results in the form of counts and fre-
quencies were calculated using Microsoft Excel.
In our paper, we use the term "thiazide class drug" to refer
to traditional thiazides (bendrofluazide and hydrochloro-
thiazide) as well as the other "thiazide-like" low-ceiling
diuretics chlorthalidone and indapamide. Guidelines
tend to recommend these interchangeably, and meta-
analysis evidence suggests they have equivalent effects.
[39]
Results
113 advertisements met our inclusion criteria. These were
composed of 27 unique advertisement designs which
appeared between 1 and 14 times each.
Table 2: Categorisation of 113 advertisements by class(es) of the antihypertensive drug(s) promoted
Drug Class Advertisements which advertised 
drug from this drug class N (%*)
Advertisements mentioning this drug 
class, or member of class, in main 
body text of advertisement N (%*)
Advertisements mentioning this drug 
class, or member of class, in entire 
advertisement, including fine print N 
(%*)
Thiazide diuretics 55 (48.7%) 64 (56.6%) 85 (75.2%)
Beta-blockers 0 (0%) 9 (8.0%) 16 (14.2%)
ACE inhibitors 44 (38.9%) 49 (43.4%) 53 (46.9%)
Angiotensin receptor blockers 29 (25.7%) 31 (27.4%) 31 (27.4%)
Calcium antagonists 26 (23.0%) 26 (23.0%) 26 (23.0%)
* The numerator for the percentages is the 113 advertisements included in the study. Percentages add to more than 100% because many 
advertisements mentioned more than one drug class.BMC Public Health 2008, 8:167 http://www.biomedcentral.com/1471-2458/8/167
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Antihypertensive drug classes
Frequencies of advertisements for members of different
antihypertensive drug classes are shown in Table 2. More
than one drug class was advertised in 41 (36.3%) adver-
tisements; of these, 28 advertised multiple products, and
34 advertised combination medicines.
Of the 55 advertisements for a thiazide class drug, 21 were
for indapamide as a single-agent pill. The remaining 34
were for combination pills, of which 14 were for indapa-
mide-containing preparations, and 20 were for hydro-
chlorothiazide-containing preparations (see table 3). We
found no advertisements for the only other thiazide class
drugs available in Australia at the time of our study: chlo-
rthalidone or bendrofluazide.
No advertisements unequivocally stated that, in the
absence of compelling indications for a different agent,
drug treatment should start with a low-dose thiazide. The
closest example to this statement, which we found in two
advertisements, was: "diuretics are suitable first-line
agents – but be wary of the long term effects of secondary
hyperglycaemia, hyperuricaemia, renal dysfunction and
electrolyte imbalance, particularly in the elderly". [40]
Seventy-three (64.6%) advertisements specifically
reminded the reader to consider antihypertensive medica-
tions other than the advertised agent(s). Fifteen advertise-
ments advised consideration of another drug instead of
the advertised agent; the other 58 advertisements advised
consideration of the other drug in addition to the adver-
tised agent.
Use of statistics
Efficacy statistics were included in 33 (29.2%) advertise-
ments. Three of these clearly stated that these statistics
were relative risk reductions. No advertisements presented
statistics in the form of absolute risk reductions, numbers
needed to treat or harm, or survival benefit. Seven adver-
tisements used risk reduction statistics without specifying
whether they were absolute or relative. These seven adver-
tisements contained nine different risk reduction claims.
Examination of the advertisements' references revealed
that all of these nine statistics were relative risk reductions
or estimates thereof derived from odds ratios. 23 adver-
tisements included statistical claims about surrogate end-
points (for example, average reduction in blood pressure
or proportion of treated patients who reached a target
blood pressure).
Statistical significance was mentioned in 7 (6.2%) adver-
tisements. Of these, 4 stated p-values. No advertisements
clearly reported confidence intervals. Three advertise-
ments mentioned a 95% confidence interval without pro-
viding the interval boundaries or stating whether or not
the results were actually statistically significant.
Other issues
Possible harm from taking the advertised drug was men-
tioned in 99 (87.6%) advertisements. In all but 2 of the
advertisements, this mention of harm was confined
entirely to the fine print.
Most advertisements (104 (92%)) mentioned prices, and
all of these described the PBS dispensed price for the med-
icine. Fifteen (13.3%) advertisements mentioned that
there was no PBS brand price premium for the advertised
agent. No advertisements explicitly compared the cost
effectiveness of different drug classes.
With regards to lifestyle interventions, no advertisements
promoted smoking cessation, weight loss, or exercise.
Alcohol and salt were the only dietary interventions dis-
cussed. Restricting alcohol intake was advised in 53
(46.9%) advertisements, but this advice was always in the
small print in the context of a potential interaction with
the advertised drug. Sodium restriction was mentioned in
54 (47.8%) advertisements, and was always confined to
small print warnings of potential adverse effects if the
advertised agents were given to a salt-restricted patient.
Table 3: Categorisation of the 55 thiazide advertisements by product(s) promoted
Thiazide advertised as: Thiazide advertised
indapamide N (%*) hydrochlorothiazide N (%*)
Single agent thiazide pill 18 (15.9%) 0 (0%)
Single agent thiazide pill plus single agent ACE inhibitor pill 3 (2.7%) 0 (0%)
Combination thiazide/ACE inhibitor pill 0 (0%) 0 (0%)
Combination thiazide/angiotensin receptor blocker pill 0 (0%) 13 (11.5%)
Combination thiazide/ACE inhibitor pill plus single agent ACE inhibitor pill 14 (12.4%) 6 (5.3%)
Combination thiazide/angiotensin receptor blocker pill plus single agent angiotensin receptor 
blocker pill
0 (0%) 1 (0.9%)
Totals 35 (31%) 20 (17.7%)
* The numerator for the percentages is the 113 advertisements included in the study.BMC Public Health 2008, 8:167 http://www.biomedcentral.com/1471-2458/8/167
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This contrasts with hypertension guidelines, which advise
decreasing dietary sodium as a means of reducing hyper-
tension. No advertisements specifically advised trialling
lifestyle changes before commencing drug treatment.
Forty-six (40.7%) advertisements promoted their drug for
a particular subgroup of patients in the main body text
(for details, see additional file 2: subgroups.pdf). Of these,
fifteen (13.3%) promoted their drug for a high-risk popu-
lation such as patients with existing macrovascular disease
or diabetic patients with hypertension.
Seventy-five (66.4%) advertisements claimed that their
drug reduced risk, danger or harm. Forty-seven (41.6%)
advertisements specifically characterised these risks as car-
diovascular or cerebrovascular events (angina, MI, TIA,
CVA or similar). Three (2.7%) advertisements suggested
the assessment, measurement or estimation of the
patient's overall cardiovascular risk. Excluding comments
on drug interactions, 3 (2.7%) advertisements recom-
mended consideration be given to pharmacological treat-
ments to lower cardiovascular risk other than
antihypertensive drugs. These were aspirin and lipid-low-
ering agents. Optimisation of diabetic control with medi-
cation was not promoted.
Discussion and conclusion
To our question of whether Australian antihypertensive
advertisements promote quality prescribing, our results
offer a mixed answer, demonstrating some important
missed opportunities for the promotion of quality use of
antihypertensives.
We found that messages to prescribers about lifestyle
interventions were almost absent from the advertise-
ments. This bias towards promotion of drugs rather than
lifestyle change is problematic because lifestyle interven-
tions should be first line treatment for many hypertensive
patients, and the foundation of ongoing treatment even
when medications are used.
Much information that is important for quality care was
underemphasised or not provided by the advertisements.
PBS costs of medications were frequently reported in
small print but cost comparisons within and between
drug classes were missing. In most advertisements, infor-
mation about harms was confined to the fine print. There
was a lack of emphasis on assessing and modifying
patients' overall cardiovascular risk.
The promotion of medications for specific target groups
may help the individualisation of therapy for the patient
in an evidence-based manner. However, advertising
claims based on data from higher-risk patients may artifi-
cially heighten a prescriber's sense of a drug's efficacy for
patients at lower risk. Similarly, the over-emphasis on rel-
ative rather than absolute statistics may create over-opti-
mistic impressions of efficacy and thus encourage over-
prescribing. [36,37] Also, if doctors and patients perceive
drugs as very effective, then they may overlook the need
for lifestyle change.
The absence of advertisements for beta-blockers may be
helpful, given that recent meta-analyses show less favour-
able outcomes for beta-blockers (particularly atenolol)
than other antihypertensive classes. [41,42] (While these
meta-analyses were not published at the time of our sam-
pling of advertisements, most of the primary trials on
which they were based were published.)
In our sample, thiazides were the most advertised class,
contrasting strongly with a previous study which found
that thiazide advertising in the New England Journal of
Medicine declined from 4.2% of advertising pages in 1985
to 0% in 1996. [10] In our study, the most frequently
advertised thiazide was indapamide. This drug is priced
almost twice as high as some other equally effective thi-
azides. The only other thiazide advertised was hydrochlo-
rothiazide, which was only advertised in combination
medications. Clearly, the advertisements do not encour-
age the prescribing of the most cost-effective drugs as a
first-line monotherapy.
Our study has several limitations. The validity of our
results may be limited by the number of advertisements
surveyed. The generalisability of our results is uncertain
because we focused only on advertisements in Australia
during 2004. We did not examine the role of imagery and
emotional appeals in the advertisements, because it is dif-
ficult to assess these objectively. We did not attempt to
assess the accuracy of therapeutic claims made in the
advertisements. We also did not attempt, for those adver-
tisements promoting antihypertensive agents for particu-
lar patient subgroups, to determine whether a particular
class of antihypertensive would have been the most
appropriate choice for that particular subgroup (in fact,
such issues are often contested in the literature).
We used evidence-based guidelines as a gold standard for
evaluating advertisements. The industry may advocate
acceptance of lower standards but we believe higher
standards for pharmaceutical promotion are required by
the Australian NMP.
Guidelines may not be perfect. Sometimes recommenda-
tions vary between guidelines. The guidelines selected for
our study varied in their recommendations about first-
line drugs so our decision to favour thiazides is open to
discussion. Guidelines may be biased by vested interests
including drug companies. [43]BMC Public Health 2008, 8:167 http://www.biomedcentral.com/1471-2458/8/167
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Our study describes the content of the advertisements, but
is not designed to show association or causation between
exposure to promotion and prescribing behaviour. Our
study should be read, though, in the context of existing
observational evidence of such associations. [11-15,44-
46]
Despite these limitations, we believe our results indicate
that many Australian print advertisements for antihyper-
tensive medications lack elements important for cost-
effective care consistent with evidence-based guidelines.
Our findings lend support to calls for increased availabil-
ity of independent prescribing information, reform of the
incentives for, and regulation of, pharmaceutical advertis-
ing,[47] and avoidance of promotional information by
prescribers. [48] These results also support calls for medi-
cal publications to be helped to develop alternative busi-
ness models rather than relying on drug promotion. [49]
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